Compare RDVT & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RDVT | SLDB |
|---|---|---|
| Founded | 2017 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 527.9M | 498.6M |
| IPO Year | 2017 | 2017 |
| Metric | RDVT | SLDB |
|---|---|---|
| Price | $37.89 | $8.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 11 |
| Target Price | ★ $62.00 | $16.36 |
| AVG Volume (30 Days) | 100.0K | ★ 1.0M |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 82.00 | 34.97 |
| EPS | ★ 0.91 | N/A |
| Revenue | ★ $90,252,000.00 | $8,094,000.00 |
| Revenue This Year | $16.31 | N/A |
| Revenue Next Year | $13.83 | N/A |
| P/E Ratio | $42.74 | ★ N/A |
| Revenue Growth | ★ 20.03 | N/A |
| 52 Week Low | $33.40 | $2.51 |
| 52 Week High | $64.14 | $8.87 |
| Indicator | RDVT | SLDB |
|---|---|---|
| Relative Strength Index (RSI) | 48.86 | 62.44 |
| Support Level | $35.84 | $5.16 |
| Resistance Level | $39.63 | N/A |
| Average True Range (ATR) | 1.86 | 0.59 |
| MACD | 0.48 | 0.07 |
| Stochastic Oscillator | 73.11 | 81.71 |
Red Violet Inc builds proprietary technologies and applies analytical capabilities to deliver identity intelligence. The company's solutions enable the real-time identification and location of people, businesses, assets, and their interrelationships. These solutions are used for purposes including identity verification, risk mitigation, due diligence, fraud detection and prevention, regulatory compliance, and customer acquisition. Its cloud-native, AI-enabled identity intelligence platform, CORE, is purpose-built for the enterprise, yet flexible enough for organizations of all sizes, bringing clarity to massive datasets by transforming data into intelligence. The company generates substantially all of its revenue from licensing its solutions.
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.